…I don't give a lot of thought to the first gen HCV PIs like telaprevir and boceprevir as it seems to me like those drugs will be relatively quickly supplanted by the 2nd gen and 3rd gen HCV PIs.
Even if this turns out to be true, the way the FDA handles the Boceprevir NDA may have consequences for the other HCV players.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”